The impact of COVID-19 on patients with neuromyelitis optica spectrum disorder; a pilot study.
Mult Scler Relat Disord
; 45: 102347, 2020 Oct.
Article
em En
| MEDLINE
| ID: mdl-32645636
ABSTRACT
Neuromyelitis optica spectrum disorder (NMOSD) is a CNS neuroinflammatory disorder, mediated by the pathogenic autoantibody aquaporin-4 (AQP4-IgG). Current treatment includes long-term use of immunomodulatory therapies, leading to increased rates of infections among this population. It is of interest therefore, to study how the COVID-19 pandemic affects NMOSD patients in terms of their disease activity. A 15-point questionnaire was administered to 33 participants living in Northern California with NMOSD, MS and other related disorders. Although none of the participants were diagnosed with COVID-19, our results show that 2 participants with NMOSD experienced new onset of neurological symptoms and 2 experienced worsening of previous neurological symptoms - suggesting a possible effect of pandemic-related stress on this CNS autoimmune disorder.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Pneumonia Viral
/
Neuromielite Óptica
/
Infecções por Coronavirus
/
Exacerbação dos Sintomas
/
Angústia Psicológica
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article